コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
2 (T) confined to pathogenic protozoa such as Trypanosoma and Leishmania JBP1 has two known functional
4 ypanosomatids, which include human pathogens Trypanosoma and Leishmania This makes Paratrypanosoma un
5 estral characters such as peptidases between Trypanosoma and Leishmania, genomic differences that wer
6 ude medically important members of the genus Trypanosoma and Leishmania, the 26/28S large subunit rib
9 ng drug target within the parasitic protozoa Trypanosoma brucei (T. brucei), the causative agent for
12 rominent defence of the unicellular parasite Trypanosoma brucei against the host immune system is a d
17 el can be applied to the characterization of Trypanosoma brucei and Leishmania spp. ribosomes as well
18 in two well-studied kinetoplastid parasites, Trypanosoma brucei and Leishmania, focusing on recent wo
21 zation of this channel to acidocalcisomes of Trypanosoma brucei and suggest that caution should be ex
23 roducts exhibit significant activity against Trypanosoma brucei and T. cruzi, featuring favorable dru
24 ickness, is caused by the protozoan parasite Trypanosoma brucei and transmitted through the bite of i
28 cells but were effective in cell cultures of Trypanosoma brucei brucei (EC(50) = 1-15 muM) and elimin
29 h a single-digit micromolar activity against Trypanosoma brucei brucei (EC50 = 2.97 muM), thus being
30 on by several protozoan parasites, including Trypanosoma brucei brucei Endocytosis and acidification
31 ate immunity against the veterinary pathogen Trypanosoma brucei brucei is conferred by trypanosome ly
33 RNase H1 loss is tolerated by the parasite Trypanosoma brucei but no work has examined the function
34 rotozoan parasites Plasmodium falciparum and Trypanosoma brucei by microscopy imaging, proving that t
44 ly assembled flagellum in the human parasite Trypanosoma brucei depends on the faithful duplication a
46 al metabolic remodeling is a hallmark of the Trypanosoma brucei digenetic life cycle because the inse
48 generates functional mitochondrial mRNAs in Trypanosoma brucei Editing is catalyzed by three distinc
52 ad of important trypanosome variants such as Trypanosoma brucei evansi that exploit mechanical transm
53 clusion ensures that the African trypanosome Trypanosoma brucei exclusively expresses only 1 of thous
54 screens were undertaken in bloodstream form Trypanosoma brucei exposed to the antifolates methotrexa
55 The bloodstream form of the human pathogen Trypanosoma brucei expresses oligomannose, paucimannose,
57 segmented gene conversion, is fundamental in Trypanosoma brucei for both VSG gene switching and for g
59 st Trypanosoma, including the human pathogen Trypanosoma brucei gambiense and Trypanosoma cruzi paras
60 uman African trypanosomiasis (HAT) caused by Trypanosoma brucei gambiense can be diagnosed in the ear
63 to replace the current treatment regimen for Trypanosoma brucei gambiense infections, following a pos
67 number of constitutive origins mapped in the Trypanosoma brucei genome is less than the minimum requi
68 l for growth and infectivity of the parasite Trypanosoma brucei However, the mechanism by which TbIP(
69 ausative agent of African sleeping sickness, Trypanosoma brucei In mitochondria of this pathogen, mos
70 eptor (TfR) of the bloodstream form (BSF) of Trypanosoma brucei is a heterodimer comprising glycosylp
80 The mitochondrion of the parasitic protozoan Trypanosoma brucei lacks tRNA genes and therefore import
81 The mitochondrion of the parasitic protozoan Trypanosoma brucei lacks tRNA genes, and thus imports al
82 screen with 176 individual bloodstream form Trypanosoma brucei lines identified PKs required for pro
83 es, putative stem-loops from L. donovani and Trypanosoma brucei nucleobase transporter mRNAs were not
85 rican trypanosomiasis is a disease caused by Trypanosoma brucei parasites with limited treatment opti
89 ation of the proliferative cell cycle of the Trypanosoma brucei procyclic life cycle stage, three sub
90 volutionarily early divergent human parasite Trypanosoma brucei proliferates through binary cell fiss
94 ition of the cysteine proteases rhodesain of Trypanosoma brucei rhodesiense and falcipain-2 of Plasmo
95 logues possess micromolar activities against Trypanosoma brucei rhodesiense and Leishmania donovani a
96 ent manner and demonstrated activity against Trypanosoma brucei rhodesiense bloodstream forms, which
97 r proteins that contribute to virulence, and Trypanosoma brucei rhodesiense EVs contain the serum res
98 stance to most African trypanosomes, but not Trypanosoma brucei rhodesiense or T.b. gambiense, which
99 gnized as a strong inhibitor of rhodesain of Trypanosoma brucei rhodesiense, endowed with a k(second)
100 ch as Plasmodium falciparum, Lassa Virus and Trypanosoma brucei rhodesiense, has resulted in elevated
101 c markers in CSF from patients infected with Trypanosoma brucei rhodesiense, using 1H nuclear magneti
102 ite concentrations in patients infected with Trypanosoma brucei rhodesiense, using liquid chromatogra
104 ved following RNAi-mediated silencing of the Trypanosoma brucei SODA ortholog suggests that SODA is e
109 the procyclic and bloodstream form stages of Trypanosoma brucei that yields viable and proliferative
111 ing the cell cycle of the protozoan parasite Trypanosoma brucei The source of components required to
112 rin uptake, we determined the structure of a Trypanosoma brucei transferrin receptor in complex with
113 ow that cytosine 32 in the anticodon loop of Trypanosoma brucei tRNA(Thr) is methylated to 3-methylcy
115 ghly motile and versatile protozoan pathogen Trypanosoma brucei undergoes a complex life cycle in the
118 ve-site residues of PRMT7 from the protozoan Trypanosoma brucei We have designed 26 single and double
119 ulation of glycosomes in live procyclic form Trypanosoma brucei When added to cells, this fluorescent
124 rganisms belonging to the phylum euglenozoa: Trypanosoma brucei, a lethal human parasite, and Euglena
125 mography structures of the 96-nm repeat from Trypanosoma brucei, a protozoan parasite in the Excavate
127 e biosynthesis pathway of the human parasite Trypanosoma brucei, an early branching eukaryote that la
129 ential for growth of the parasitic protozoan Trypanosoma brucei, enabling the study of its function i
131 th sleeping sickness, caused by the parasite Trypanosoma brucei, have disruptions in both sleep timin
132 ed to TbKHC1, an orphan kinesin H chain from Trypanosoma brucei, inhibited T. musculi excreted/secret
133 receptor of the African trypanosome species, Trypanosoma brucei, is expressed when the parasite is in
138 the causative agent, the protozoan parasite Trypanosoma brucei, occurs through receptor-mediated end
139 e effects of the sleeping sickness parasite, Trypanosoma brucei, on sleep patterns in mice, under bot
143 t that CRK1, a G1 cyclin-dependent kinase in Trypanosoma brucei, regulates anterograde protein traffi
144 ains of TR from the basal eukaryotic species Trypanosoma brucei, revealing the ancestry of TR compris
145 ruzi, the causative agent of Chagas disease; Trypanosoma brucei, the causative agent of African sleep
146 13b ortholog in the evolutionarily divergent Trypanosoma brucei, the causative agent of African sleep
147 , which had been identified as a hit against Trypanosoma brucei, the causative agent of human African
148 es (PKs) are a class of druggable targets in Trypanosoma brucei, the causative agent of Human African
149 point for the synthesis of new hits against Trypanosoma brucei, the causative agent of human African
157 resistant strains of the protozoal pathogens Trypanosoma brucei, Trypanosoma congolense and Leishmani
158 nt parasites and include the human pathogens Trypanosoma brucei, Trypanosoma cruzi, and Leishmania sp
160 nd biogenesis of the array, with emphasis on Trypanosoma brucei, Trypanosoma cruzi, and Leishmania, w
161 pathway and its enzymes have been studied in Trypanosoma brucei, Trypanosoma cruzi, and various Leish
163 its application to the pathogenic protozoan, Trypanosoma brucei, using hyperpolarized (13)C1 pyruvate
167 in the causative agent of sleeping sickness, Trypanosoma brucei, with that of human erythrocytes, and
180 ositol pyrophosphate biosynthetic pathway in Trypanosoma brucei: inositol polyphosphate multikinase (
181 of unicellular parasitic flagellate protozoa.Trypanosoma bruceispecies and Trypanosoma cruziare the m
185 o-infections with other trypanosome species (Trypanosoma congolense and Trypanosoma vivax) are common
186 mal African trypanosomiasis (AAT), caused by Trypanosoma congolense and Trypanosoma vivax, remains on
192 the authors present a 2.5-A structure of the Trypanosoma cruzi 60S ribosomal subunit and propose a mo
193 disease is caused by the protozoan parasite Trypanosoma cruzi and affects 5-8 million people in Lati
194 time for the simultaneous detection of anti-Trypanosoma cruzi and anti-Leishmania infantum antibodie
195 Chagas disease is caused by the parasite Trypanosoma cruzi and is an important cause of morbidity
196 have been considered as virulence factors of Trypanosoma cruzi and Leishmania spp., and have been dem
197 gondii and kinetoplastid protozoa, including Trypanosoma cruzi and Leishmania spp., cause millions of
198 centrating on Mycobacterium tuberculosis and Trypanosoma cruzi as examples of bacterial and parasitic
201 reference perspective, cruzain, an essential Trypanosoma cruzi cysteine protease, is highly homologou
205 e extreme genetic diversity of the protozoan Trypanosoma cruzi has been proposed to be associated wit
209 response plays a crucial role in controlling Trypanosoma cruzi infection and parasite burden, but it
211 nic Chagas disease cardiomyopathy, caused by Trypanosoma cruzi infection, is a major cause of heart f
220 The insect-transmitted protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disea
228 s were identified as potential inhibitors of Trypanosoma cruzi replication, a parasite responsible fo
229 es, we determined the 2.5-A structure of the Trypanosoma cruzi ribosome large subunit by single-parti
231 s from a screen against the related parasite Trypanosoma cruzi Subsequent optimization of the chemica
233 pest insect that has the ability to transmit Trypanosoma cruzi under experimental laboratory conditio
234 as disease, caused by the protozoan parasite Trypanosoma cruzi, affects 7 million people in Latin Ame
235 gas disease is a chronic infection caused by Trypanosoma cruzi, an intracellular protozoan parasite.
237 The trypanosomatids Trypanosoma brucei, Trypanosoma cruzi, and Leishmania spp. are flagellate eu
238 lude the human pathogens Trypanosoma brucei, Trypanosoma cruzi, and Leishmania spp., which in humans
239 array, with emphasis on Trypanosoma brucei, Trypanosoma cruzi, and Leishmania, which cause life-thre
241 ng infection with the intracellular parasite Trypanosoma cruzi, as evidenced by transcriptome and cyt
243 sed by infection with the protozoan parasite Trypanosoma cruzi, is a leading cause of heart disease (
245 used by the intracellular protozoan parasite Trypanosoma cruzi, is a public health problem affecting
246 ysteine protease of the parasitic protozoan, Trypanosoma cruzi, is an important drug target for Chaga
247 Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic in Latin America and affec
249 s' disease, caused by the protozoan parasite Trypanosoma cruzi, is the most common cause of cardiac-r
250 y infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp. and Trypanosoma bruce
251 a novel mechanism used by diverse pathogens (Trypanosoma cruzi, Listeria monocytogenes, and adenoviru
252 mice with the myotropic Colombiana strain of Trypanosoma cruzi, parasites persisted in tissue at low
254 of fire ants against the protozoan parasite Trypanosoma cruzi, the aetiologic agent of Chagas diseas
257 ted with AT during part of their life cycle: Trypanosoma cruzi, the causative agent of Chagas disease
260 (NMT), an essential and druggable target in Trypanosoma cruzi, the causative agent of Chagas' diseas
267 role of CD43 in the immune response against Trypanosoma cruzi, the protozoan parasite that causes Ch
269 g resistance of the Chagas disease parasite, Trypanosoma cruzi, to current therapies are not well und
270 elivers Gzms into three protozoan parasites (Trypanosoma cruzi, Toxoplasma gondii and Leishmania majo
271 C(50) within the low nanomolar range against Trypanosoma cruzi, with very high selectivity toward the
272 ar why only a proportion of children born to Trypanosoma cruzi-infected mothers acquire the infection
273 hmania-like flagellum attachment zone, and a Trypanosoma cruzi-like cytostome are ancestral features,
283 idate clathrin-associated proteins (CAPs) in Trypanosoma cruzi; the cohort includes orthologs of many
284 llate protozoa.Trypanosoma bruceispecies and Trypanosoma cruziare the major agents of human trypanoso
285 testing identified the infecting species as Trypanosoma evansi.Despite relapsing 6 weeks after compl
287 s show significant cellular activity against Trypanosoma, including the human pathogen Trypanosoma br
288 range of available chemotherapeutics against Trypanosoma is limited, and the existing therapies are p
290 hosts) trypanosomatid species of the genera Trypanosoma, Leishmania, and Phytomonas, but only fragme
292 examination of blood revealed infection with Trypanosoma METHODS: Microscopic observation, polymerase
293 ced in macrophages during mouse infection by Trypanosoma musculi, a natural parasite of this host.
296 identify PEX14 as an "Achilles' heel" of the Trypanosoma suitable for the development of new therapie
298 panosome species (Trypanosoma congolense and Trypanosoma vivax) are common in animals, generating the
299 (AAT), caused by Trypanosoma congolense and Trypanosoma vivax, remains one of the most important liv